Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis)

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 448-452

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study

By Meneghini L. F.   Dornhorst A.   Sreenan S.  

Current Medical Research and Opinion, Vol. 25, Iss. 4, 2009-04 ,pp. : 1029-1035

Informa Healthcare

Access to resources Recommend Favorite

One‐year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal‐time insulin: the EDITION 1 12‐month randomized trial, including 6‐month extension

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 9, 2015-09 ,pp. : 835-842

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 71, Iss. 12, 2017-12 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glycaemic control and self‐management behaviours in Type 2 diabetes: results from a 1‐year longitudinal cohort study

By  

DIABETIC MEDICINE, Vol. 32, Iss. 9, 2015-09 ,pp. : 1247-1254

John Wiley & Sons Inc

Access to resources Recommend Favorite